Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crizotinib and Enzalutamide in mCRPC
NCT02207504Phase 1Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Aug 2014
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of crizotinib in prostate cancer (PCa), sponsored by Dana-Farber Cancer Institute. Primary endpoint: Rate of dose limiting toxicity at 28 days. Started Aug 2014; status: completed.
02
Drugs
crizotinib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02207504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02207504.